The federal Medicare prescription drug benefit program, known as Part D, is now in its sixth year, and its costs are coming in 45 percent lower than initially projected. The average monthly premium is less than half of the original forecasts, and deductibles are decreasing.
For the original version including any supplementary images or video, visit http://www.stltoday.com/news/opinion/mailbag/letters-to-the-editor/preserving-medicare-part-d-is-a-win-win/article_326dc73e-4419-5bc9-9a09-91dc36243641.html
MiMedx Receives Additional Medicare Reimbursement Coverage for EpiFix®
<img src='http://medicaretruths.com/wp-content/uploads/2010/09/Medicare-Part-A-Chart.png' click this link width=’200px’ style=’float:left;padding:5px’ />
12, 2013 /PRNewswire/ –MiMedx Group, Inc.(NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, CGS, has confirmed that the Company’s wound care allograft, EpiFix, has received reimbursement coverage from CGS. The coverage by CGS now brings the total Medicare Administrative Contractors (MACs) covering EpiFix to six of the eight and 86% of Medicare beneficiaries will now be eligible for coverage for EpiFix products. “We have been persistent in executing our strategy to gain MAC coverage throughout the country,” said Parker H.
For the original version including any supplementary images or video, visit http://www.bizjournals.com/prnewswire/press_releases/2013/12/12/CL32695